CJC-1295 vs Sermorelina
CJC-1295 is mainly studied for body composition, recovery, gh signaling. while Sermorelina is studied for recovery, sleep, vitality, composition. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| CJC-1295 | Sermorelina | |
|---|---|---|
| Category | Hormonal/Sexual | Hormonal/Sexual |
| Studied for | Body composition, recovery, GH signaling. | Recovery, sleep, vitality, composition. |
| How it acts | An analog studied for its relationship with the growth-hormone release axis; analyzed for its long-acting kinetics. | An analog studied for its relationship with natural growth-hormone release via the hypothalamic axis. |
| Evidence level | Limited human evidence | Human trials available |
How they differ
Although sometimes mentioned together, CJC-1295 and Sermorelina do not target the same thing. CJC-1295: An analog studied for its relationship with the growth-hormone release axis; analyzed for its long-acting kinetics. Sermorelina: An analog studied for its relationship with natural growth-hormone release via the hypothalamic axis.
See full entry: CJC-1295 → · See full entry: Sermorelina →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between CJC-1295 and Sermorelina?
CJC-1295 targets body composition, recovery, gh signaling. and Sermorelina targets recovery, sleep, vitality, composition. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, Sermorelina has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for CJC-1295 vs Sermorelina or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultshuman J Clin Endocrinol Metab · 2006 · PMID 16352683 →
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analoghuman J Clin Endocrinol Metab · 2006 · PMID 17018654 →
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mousepreclinical Am J Physiol Endocrinol Metab · 2006 · PMID 16822960 →
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potionsreview Subst Use Misuse · 2016 · PMID 26771670 →
- Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Grouphuman J Clin Endocrinol Metab · 1996 · PMID 8772599 →
- A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiencyhuman Acta Paediatr Suppl · 1993 · PMID 8329830 →
- Intranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency: effects on growth hormone secretion and growthhuman Acta Paediatr Suppl · 1993 · PMID 8329828 →
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and womenhuman J Clin Endocrinol Metab · 1997 · PMID 9141536 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.